| Autor: |
Ryo Itabashi, Shoichiro Sato, Junji Takasugi, Toshihiro Ide, Naoto Kinoshita, Soichiro Matsubara, Shunya Takizawa, Yoshinari Nagakane, Kyohei Fujita, Kyoko Higashida, Satoshi Okuda, Sohei Yoshimura, Satoshi Shibuya, Takeshi Yoshimoto, Hideki Matsuoka, Hiroshi Yamagami, Yoshitaka Yamaguchi, Yoshiaki Shiokawa, Kazumi Kimura, Masatoshi Koga, Yasuhiro Ito, Daisuke Ando, Masaya Kumamoto, Yasuhiro Hasegawa, Kenji Kamiyama, Tomoaki Kameda, Tadashi Terasaki, Kazuomi Kario, Masayuki Shiozawa, Keisuke Tokunaga, Teppei Kamimura, Yoshiki Yagita, Shoji Arihiro, Kenichi Todo, Kazutoshi Nishiyama, Kazunori Toyoda, Kazuhiro Takamatsu, Yasushi Okada, Kazunari Homma, Takayuki Matsuki |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Circulation Journal. 82:1935-1942 |
| ISSN: |
1347-4820
1346-9843 |
| DOI: |
10.1253/circj.cj-18-0067 |
| Popis: |
BACKGROUND We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods and Results:NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS2and discharge modified Rankin Scale scores than warfarin users (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
